<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052960</url>
  </required_header>
  <id_info>
    <org_study_id>GEXMab52201</org_study_id>
    <nct_id>NCT02052960</nct_id>
  </id_info>
  <brief_title>CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer</brief_title>
  <acronym>RESGEX</acronym>
  <official_title>Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX™ Plus CT in Comparison to Cetuximab Plus CT in Patients With Stage III/IV Recurrent and/or Metastatic SCCHN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotope GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycotope GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the efficacy of CetuGEX™ for the treatment of patients
      with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in
      combination with platinum-based chemotherapy) in terms of progression-free survival (PFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indication: First line systemic treatment for stage III/IV recurrent and/or metastatic
      squamous cell carcinoma of the head and neck (SCCHN)

      Primary Objective:

      To evaluate the efficacy of CetuGEX™ for the treatment of patients with stage III/IV
      recurrent and/or metastatic SCCHN as compared to cetuximab (both in combination with
      platinum-based chemotherapy) in terms of progression-free survival (PFS).

      Secondary Objectives:

      To evaluate further efficacy criteria, safety and quality of life (QoL) of patients with
      stage III/IV recurrent and/or metastatic SCCHN treated with CetuGEX™ as compared to cetuximab
      (both in combination with platinum-based chemotherapy).

      To assess pharmacokinetic (PK) parameters and profiles of CetuGEX™. To assess efficacy and
      safety based on genetic markers for immune response (Fc-gamma receptor [FcγR] allotypes) and
      biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 15, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of CetuGEX™ (Tomuzotuximab) as compared to Cetuximab in terms of progression-free survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The primary objective of the study is to evaluate the efficacy of CetuGEX™ for the treatment of patients with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in combination with platinum-based chemotherapy) in terms of PFS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Tomuzotuximab plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg/day 0, 930 mg/day 1, followed by 720 mg weekly administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab plus chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg/m2 on day 1, followed by 250 mg/m2 weekly administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tomuzotuximab</intervention_name>
    <description>720 mg i.v. weekly</description>
    <arm_group_label>Tomuzotuximab plus chemotherapy</arm_group_label>
    <other_name>CetuGEX™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>250 mg/sqm BSA i.v. weekly</description>
    <arm_group_label>Cetuximab plus chemotherapy</arm_group_label>
    <other_name>Erbitux®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)</description>
    <arm_group_label>Tomuzotuximab plus chemotherapy</arm_group_label>
    <arm_group_label>Cetuximab plus chemotherapy</arm_group_label>
    <other_name>Combination of Cisplatin and 5-Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed recurrent and/or metastatic EGFR-positive SCCHN
             not eligible for local treatment.

          2. Patients with measurable disease according to Response Evaluation Criteria in Solid
             Tumors (RECIST) 1.1.

          3. Patients aged at least 18 years at screening.

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          5. Minimum life expectancy of 3 months.

          6. Tissue samples available for specific disease and therapy related biological
             assessments.

          7. If female and of childbearing potential, is non-lactating and has negative pregnancy
             test results at screening and prior to randomization.

          8. If female, is either not of childbearing potential or using highly effective
             contraceptives.

          9. Willing and able to comply with the protocol.

         10. Willing and able to provide written informed consent.

        Exclusion Criteria:

          1. Prior systemic chemotherapy (except if given as part of a multimodal treatment for
             locally advanced disease which was completed more than 6 months prior to screening).

          2. Cetuximab or other EGFR targeting agent treatment (except if given as part of a
             multimodal treatment for locally advanced disease which was completed more than 6
             months prior to screening).

          3. Surgery (other than minor interventions like diagnostic biopsy or intravenous port
             implantation) or irradiation within 30 days before randomization.

          4. Concomitant anti-tumor therapy or concomitant immunotherapy.

          5. Concomitant corticosteroid treatment unless specified within the protocol.

          6. Clinical evidence of brain metastasis or leptomeningeal involvement.

          7. Patients with nasopharyngeal tumors.

          8. Concomitant malignant disease, except for adequately treated tumors with high
             likelihood of being cured (e.g., basal cell cancer of the skin, cervical cancer or
             breast cancer in situ). Patients with other previous malignancies but without evidence
             of disease for at least 5 years will be allowed to enter the study.

          9. Patients with renal or hepatic impairment.

         10. Clinically active infections ≥ Grade 2 using National Cancer Institute (NCI) Common
             Terminology Criteria for Adverse Events (CTCAE) version 4 and/or requiring intravenous
             antibiotics.

         11. Known active hepatitis B or C.

         12. Known human immunodeficiency virus (HIV) infection.

         13. Myocardial infarction within 6 months prior to screening.

         14. Symptomatic congestive heart failure (New York Heart Association [NYHA] Grade 3 or 4),
             unstable angina pectoris within 6 months prior to screening, significant cardiac
             arrhythmia, history of stroke or transient ischemic attack within 1 year prior to
             screening.

         15. History of keratitis requiring medical interventions within the last 5 years.

         16. Patients with any other disorder that, in the opinion of the investigator, might
             interfere with the conduct of the study.

         17. Patients with an unstable condition (e.g., psychiatric disorder, a recent history of
             drug or alcohol abuse, interfering with study compliance, within 6 months prior to
             screening) or otherwise thought to be unreliable or incapable of complying with the
             requirements of the protocol.

         18. Patients institutionalized by official means or court order.

         19. Receipt of any other investigational medicinal product within the last 30 days before
             randomization or any previous CetuGEX™ administration.

         20. Prior allergic reaction to a monoclonal antibody, grade 3 infusion related reaction
             (IRR) or any grade 4 reaction to a monoclonal antibody.

         21. Known sensitivity to any component of the investigational medicinal product (IMP) and
             medication used in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Keilholz, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>St Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Milan</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Warsaw</city>
        <zip>2781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Brasov</city>
        <zip>500091</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Clui-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Craiova</city>
        <zip>200385</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Ploiesti</city>
        <zip>100011</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Timisoara</city>
        <zip>300167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Madrid</city>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

